22:52 , May 2, 2019 |  BC Extra  |  Clinical News

May 2 Clinical Quick Takes: Biogen, GSK, Celgene/bluebird, Genkyotex

Biogen's ALS candidate reduces SOD1 protein levels in CSF  Biogen Inc. (NASDAQ:BIIB) will present on May 7 at the American Academy of Neurology meeting the interim Phase I/II data of tofersen that had prompted it...
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
17:30 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

Genkyotex S.A. (Euronext:GKTX) reported data from a prespecified interim analysis of 92 evaluable patients with primary biliary cholangitis in a Phase II trial showing that twice-daily GKT831 led to a significant 23% reduction in mean...
23:05 , Nov 5, 2018 |  BC Extra  |  Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

Genkyotex S.A. (Euronext:GKTX) reported data from a prespecified interim analysis of 92 evaluable patients with primary biliary cholangitis in a Phase II trial showing that twice-daily GKT831 led to a significant 23% reduction in mean...
19:10 , Aug 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer Patient sample and mouse studies suggest inhibiting NOX4 could help treat cancer. In samples from patients with squamous cell carcinoma of the head and neck (SCCHN), esophageal cancer, colorectal cancer, breast cancer or...
00:18 , Aug 8, 2017 |  BC Extra  |  Preclinical News

Researchers suggest inhibiting NOX4 could treat cancer

In a paper published in the Journal of the National Cancer Institute , researchers at the University of Southampton showed that inhibiting NADPH oxidase 4 (NOX4) in cancer-associated fibroblasts can abrogate the tumor-promoting function of...
18:23 , Jul 3, 2017 |  BC Week In Review  |  Clinical News

Genkyotex begins Phase II of GKT831 in PBC

Genkyotex S.A. (Euronext:GKTX) began a Phase II trial to evaluate once- and twice-daily 400 mg GKT831 (formerly GKT137831) for 24 weeks in 102 patients with primary biliary cholangitis (PBC) and an inadequate response to ursodeoxycholic...
18:14 , May 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Depression Mouse studies suggest inhibiting NOX1 could help treat depression. In two mouse models of depression, NOX1 knockdown decreased social avoidance and acute stress-induced immobility compared with normal expression. Next steps could include identifying...
21:07 , Dec 30, 2016 |  BC Week In Review  |  Company News

Genticel, Genkyotex deal

The companies will merge to form a publicly traded entity that plans to develop Genkyotex's pipeline of NADPH oxidase inhibitors to treat fibrotic diseases. Genkyotex’s shareholders will receive about 11.8 Genticel shares for each Genkyotex...
00:19 , Dec 23, 2016 |  BC Extra  |  Financial News

Genkyotex finds public path via Genticel merger

Genkyotex S.A. (Plan-les-Ouates, Switzerland) and Genticel S.A. (Euronext:GTCL) are merging to form a publicly traded entity that intends to develop Genkyotex's pipeline of NADPH oxidase inhibitors to treat fibrotic diseases. The Swiss biotech's shareholders will...